retatrutide drug retatrutide for Weight Loss: TRIUMPH-1 Results, Cost, Insurance Triple Agonist Peptides Explained: Retatrutide,

And current data reiterates the potential benefits of GLP-1 drugs for weight loss, with a recent study finding that medications like Wegovy that are prescribed for weight loss may reduce the risk of heart attack, stroke or heart-related death in people with cardiovascular disease

To address these challenges, the brand debuted Protein Granola

Indirect comparisons suggest that, in terms of side effects, retatrutide may be most similar to the triple-strength, 7.2 mg Wegovy dose that the FDA approved in 2026

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: A randomised, controlled, double-blind, ascending dose and phase 2a study